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In this study, we examined the ability of human T-cell leukemia virus type I (HTLV-I) Gag and Gag-Pro to assemble immature
virus-like particles (VLPs) and bud from insect and mammalian cells. Transmission electron microscopy of insect cells
infected with a recombinant baculovirus carrying the entire gag gene revealed that Pr53Gag is targeted to the plasma
membrane, where it extensively accumulates and forms electron-dense evaginations. However, no particles could be
detected either inside the cells or in the culture supernatants. With the Gag-Pro-expressing construct, we observed
HTLV-I-specific cytoplasmic proteolysis of the Gag precursor, but again no particle released in the culture supernatants.
Transmission electron microscopic analysis of insect cells expressing Gag-Pro polyprotein revealed large vacuoles in the
cytoplasm and no budding particles at the plasma membrane. In contrast, human immunodeficiency virus type 1 Gag
polyprotein expressed in insect cells is able to release VLPs. These data showed that unlike other retroviruses, Pr53Gag is
unable to be released as immature VLPs from insect cells. To determine whether the block in particle budding and release
is due to an intrinsic property of Pr53Gag or the absence of essential cellular factors in insect cells, we expressed Gag and
Gag-Pro polyproteins in human 293 cells. The results indicate that Pr53Gag and p24 capsid are released within particles into
the culture supernatants of human 293 cells. We found that the myristylation of the N-terminal glycine residue is essential
for Gag release. Altogether, these results strongly suggest that the proper assembly of HTLV-I particles is dependent on
mammalian host cell factors. © 2000 Academic Press
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Human T-cell leukemia virus type I (HTLV-I) belongs to
the HTLV/bovine leukemia virus (BLV) group, whose vi-
ruses share a moderately complex genomic organization
(Coffin, 1996). HTLV-I encodes four major genes, gag,
pro, pol, and env, as well as the distinctive X region
ocated in the 39 end of the genome. The viral proteins
ag, Pro, and Pol are expressed as precursor polypro-
eins Pr53Gag, Pr76Gag-Pro, and Pr160Gag-Pro-Pol, respectively.
The Env glycoprotein is synthesized as a 61-kDa precur-
sor protein, which is subsequently glycosylated and
cleaved into cell-surface (gp46) and transmembrane
(gp21) proteins (Weiss et al., 1985). The expression of the
pol gene requires two ribosomal frame-shiftings:
one between gag and pro that generates Pr76Gag-Pro
and another one between pro and pol that leads to
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597Pr160Gag-Pro-Pol. These precursor proteins encode the viral
rotease (PR), reverse transcriptase (RT), and integrase
IN). Cleavage of the Gag polyprotein by PR generates
he matrix MA(p19), the capsid CA(p24), and the nucleo-
apsid NC(p17) proteins (Nam et al., 1988).
HTLV-I virus particle formation seems to follow a path-
ay, like that of type C retroviruses, that includes four
ajor dynamic processes. Gag, Gag-Pro, and Gag-Pro-
ol polyproteins are targeted to the plasma membrane,
here they assemble to generate a crescent-shaped
orm (Gelderblom, 1991; Miyauchi and Maruyama, 1990;
almer and Goldsmith, 1988) and most likely incorporate
nvelope glycoproteins. This structure evolves to a pe-
ipheral dark ring that buds and then pinches off from the
lasma membrane. During or shortly after budding from
he plasma membrane, the dark ring collapses to a
entral electron-dense core. At this stage, the viral pro-
ease probably cleaves the Gag polyproteins and
onverts the nascent immature particle into a mature
article.
Previous reports have shown that numerous retroviral
ag polyproteins, including HTLV-2, BLV, and human
mmunodeficiency virus type 1 (HIV-1) Gag, when ex-
ressed alone, assemble into virion-like particles (VLPs)
nd bud from insect and mammalian cells (Delchambre
0042-6822/00 $35.00
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598 BOUAMR ET AL.et al., 1989; Gheysen et al., 1989; Hu et al., 1990; Kaker et
al., 1999; Luo et al., 1990; Mergener et al., 1992;
Morikawa et al., 1991; Rasmussen et al., 1990; Royer et
al., 1991; Shioda and Shibuta, 1990; Smith et al., 1990;
Sommerfelt et al., 1993; Takahashi et al., 1999; Vernon et
al., 1991; Wills et al., 1989). Nevertheless, it was also
reported that some insect cells exhibit a defect in the
release of D- and C-type virus particles, suggesting the
requirement of host cell factors in the retroviral morpho-
genesis (Parker and Hunter, 2000). Extensive studies of
different retroviral Gag proteins have led to the identifi-
cation of small functional domains essential for particle
production (Bennett et al., 1993; Parent et al., 1995; Pep-
nsky et al., 1986; Puffer et al., 1997; Weldon and Wills,
993; Wills et al., 1991, 1994; Yasuda and Hunter, 1998;
hou et al., 1994). Interactions between Gag polyproteins
nd cellular proteins were also examined (Garnier et al.,
996; Luban et al., 1993). Such information regarding
TLV-I Gag polyprotein has not yet been obtained. Two
ain reasons are responsible for the delay in determin-
ng the role of structural and enzymatic proteins in the
ynamic processes leading to HTLV-I particle formation:
1) free viral particles are poorly or not infectious and
ransmission of the virus seems to occur mainly via
ell-to-cell contact, and (2) the lack of an infectious
olecular clone until recently (Derse et al., 1995; Zhao
t al., 1995).
In this study, we examined the ability of HTLV-I Gag
olyprotein to direct particle formation in two expression
ystems. Our data showed that HTLV-I Pr53Gag polypro-
teins, expressed in insect cells, accumulated at the
plasma membrane but, unlike other retroviruses, did not
assemble into VLPs that release by budding from the
plasma membrane. Moreover, expression of Gag-Pro
polyprotein in insect cells yielded cleavage in mature
proteins, indicating synthesis of active protease. In con-
trast, no VLPs were found in the culture medium. How-
ever, in human 293 cells, Gag polyproteins were re-
leased as enveloped particles into the culture media.
Altogether, these results demonstrate that HTLV-I Pr53Gag
polyprotein assembles in a cell type-dependent manner
and strongly suggest the involvement of an unknown
cellular factor or factors in the final stages of HTLV-I
particle assembly.
RESULTS
Expression of HTLV-I Gag precursor polyprotein in
insect cells
To express HTLV-I Pr53Gag polyprotein, we constructed
the recombinant baculovirus Autographa californica nu-
clear polyhedrosis virus (AcNPV)gag that contains the
entire HTLV-I Pr53Gag protein coding sequence under the
ontrol of the strong polyhedrin promoter. AcNPVgag-
nfected Sf9 cells were harvested 24, 36, 48, and 72 h
ostinfection. Cell lysates were then characterized byestern blot analysis using a monoclonal antibody to
19. As shown in Fig. 1, an unique 53-kDa protein was
ynthesized at 36 h postinfection (lane 4). The molecular
eight of this protein was consistent with the predicted
eight of the HTLV-I Gag precursor as deduced from the
ucleotide sequence (Gray et al., 1989). At 48 and 72 h
fter infection, larger amounts of Pr53Gag were detected
(Fig. 1, lanes 5 and 6). The level of Gag expression
appears to be high based on (1) the intensities of the
signals obtained by immunoblotting and (2) the fact that
Pr53Gag can be easily identified by Coomassie blue stain-
ng (data not shown). Three days postinfection, two
leavage products were also recognized and probably
esulted from proteolysis by host cell proteases (Fig. 1,
ane 6).
To localize Pr53Gag in insect cells, thin sections of cells
nfected with AcNPVgag were prepared. Transmission
lectron microscopy (TEM) showed the cytoplasmic sur-
ace of the plasma membrane heavily bounded by
arked evaginations (Figs. 2A and 2B). In addition, ex-
mination at higher magnification revealed an extensive
ccumulation of electron-dense material beneath the
lasma membrane (Fig. 2B). Structures with an irregular
ize and shape and electron-dense material located on
he inner side of the membrane were found at the pe-
iphery of the cells (Fig. 2B). However, no typical budding
r released VLP was observed. None of these structures
ere found in wild-type AcNPV-infected Sf9 cells (data
ot shown). Immunogold labeling experiments using a
onoclonal antibody to p24 also showed that large
mounts of Pr53Gag protein were localized at the cell
membrane and at the periphery of protrusions observed
at the plasma membrane, whereas no gold particles
were found in wild-type AcNPV-infected insect cells la-
FIG. 1. Expression of Pr53Gag precursor in insect cells. Sf9 cells
infected with AcNPVgag were harvested 24 h (lane 3), 36 h (lane 4), 48 h
(lane 5), or 72 h (lane 6) postinfection, and cell lysates were analyzed
by SDS–PAGE and immunoblotted with a monoclonal anti-p19MA an-
tibody. No Pr53Gag was detected in extracts from either uninfected (lane
1) or wild-type AcNPV-infected Sf9 cells (lane 2). The positions of
Pr53Gag and molecular mass markers (in kDa) are indicated.beled with the same antibody or when the experiment
was performed in the absence of the primary antibody
599HTLV-I PARTICLE RELEASE FROM INSECT AND MAMMALIAN CELLSFIG. 2. Thin-section electron microscopy of Sf9 cells harvested 48 h postinfection with recombinant baculovirus AcNPVgag (A and B). (B) The
plasma membrane is bounded by marked evaginations. Black arrows indicate electron-dense material beneath the plasma membrane. Magnification:
A, 37500; B, 394,000. Bars: A, 1.33 mm; B, 105 nm.
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600 BOUAMR ET AL.anti-p24 (data not shown). Altogether, these data showed
that HTLV-I Pr53Gag proteins were abundantly expressed
in insect cells; in the cytoplasm, large amounts of Gag
polyproteins were targeted to the plasma membrane,
where they aggregated, forming electron-dense evagina-
tions but no budding VLPs.
Analysis of Gag secretion
To examine the nature of Pr53Gag polyproteins released
in the culture media, a two-step sucrose gradient method
(Sommerfelt et al., 1993) was performed. This method
llows the partial separation of baculovirus particles
rom enveloped VLPs. Baculoviruses were first pelleted
y sedimentation through a 40% sucrose cushion (pellet
0%). The VLPs, which have been arrested at the inter-
ace, were then pelleted through a 25% sucrose cushion
pellet 25%), whereas the soluble Gag polyproteins re-
ain in the supernatant fraction. The validity of this
ssay in our experiment was confirmed by using a pos-
tive control recombinant baculovirus AcNPVgag12, which
was previously described to yield expression and re-
lease of the entire HIV-1 Gag polyprotein (Royer et al.,
1991).
Culture media of insect cells infected with either Ac-
NPVgag or AcNPVgag12 were harvested 48 h postinfec-
tion and subjected to two-step sucrose gradient analy-
FIG. 3. (A) Two-step sucrose gradient analysis of Gag released into
culture medium of Sf9 cells infected with AcNPVgag. Proteins from cell
extracts (lane 1) or pelleted from the culture medium through the 40%
sucrose cushion (lane 3) or through the 25% sucrose cushion (lane 2)
were analyzed by SDS–PAGE and immunoblotted with a monoclonal
anti-p19MA antibody. (B) Two-step sucrose gradient analysis of HIV-1
Gag proteins released in culture medium of Sf9 cells infected with
AcNPVgag12. Proteins from cell extracts (lane 1) or pelleted from the
ulture medium through the 40% sucrose cushion (lane 3) or through
he 25% sucrose cushion (lane 2) were analyzed by SDS–PAGE and
mmunoblotted with a serum from an HIV-positive patient. The positions
f HIV-1 Gag and molecular mass markers (in kDa) are indicated.sis. Western blot analysis using a monoclonal antibody
to p19 showed (Fig. 3A) that Pr53Gag polyproteins werehighly expressed in the cells (Fig. 3A, lane 1); however, a
low amount was released (Fig. 3A, lanes 2 and 3). In the
culture medium, Gag proteins were predominantly
present in pellet 40% (Fig. 3A, lane 3); a weak signal of
Pr53Gag was detected in pellet 25% (Fig. 3A, lane 2). No
soluble Gag was found in the supernatant fraction (data
not shown). These results showed that most of the Gag
polyproteins produced in insect cells remained cell as-
sociated. In regard to HIV-1 Gag polyprotein, the use of
serum from an HIV-1-positive patient showed (Fig. 3B)
that high amounts of HIV-1 Gag (55 kDa) were expressed
in the cells (Fig. 3B, lane 1). In the culture medium, in
contrast to HTLV-I Gag polyprotein, a large amount of
HIV-1 Gag (55 kDa) was sedimented in pellet 25%,
whereas much less was found in pellet 40% (Fig. 3B,
compare lanes 2 and 3). Indeed, by using TEM and
two-step sucrose gradient analyses, we previously de-
scribed that HIV-1 Gag polyprotein expressed in insect
cells is released from the plasma membrane as VLPs
that sedimented in the pellet 25% (Royer et al., 1992).
Consistently, in the present study, the HIV-1 VLPs re-
leased from insect cells sedimented mainly in pellet 25%.
To further characterize the pelletable forms of HTLV-I
Pr53Gag, pellets 40% and 25% were examined by TEM.
he results showed that both pellets (Figs. 4A and 4B)
ontain exclusively baculoviruses and no typical retrovi-
al VLPs. Therefore, the small amount of Gag found in the
ulture medium was associated with the baculovirus
articles, supporting the observation earlier that Pr53Gag
polyprotein accumulated at the plasma membrane of
insect cells but did not bud and release typical retroviral
VLPs.
Role of HTLV-I protease in particle morphogenesis
To examine a possible effect of the protease and its
flanking regions on Gag particle morphogenesis and
release, a recombinant baculovirus AcNPVgag-pro, con-
taining the entire gag and pro genes and the 59 part of
the pol gene, was constructed. The proteins expressed
by AcNPVgag-pro in insect cells were characterized by
Western blot analysis. Using serum from an HTLV-I-pos-
itive patient, prominent bands with molecular mass of 19
and 24 kDa were detected, as well as a less abundant
protein that migrated at 53 kDa and appeared to be the
product of the gag protein (Fig. 5, lane 3). Two major
products (53 and 19 kDa) were detected by using a
monoclonal antibody to p19 (Fig. 5, lane 1), whereas a
doublet (24–25 kDa) and a protein with an estimated
molecular mass of 37 kDa, corresponding to an interme-
diate precursor protein, were observed by using a mono-
clonal antibody to p24 (Fig. 5, lane 2). Finally, by using an
anti-protease monoclonal antibody (Mamoun et al.,
1997), a protein with the size predicted for the viral
protease was detected (data not shown). Based on the
specific maturation of the Pr53Gag into p24 capsid and
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601HTLV-I PARTICLE RELEASE FROM INSECT AND MAMMALIAN CELLSp17 matrix proteins, these data indicated that Gag-Pro
polyprotein was translated and an active HTLV-I pro-
tease was produced.
To analyze insect cells expressing Gag-Pro polypro-
teins, thin sections of Spodoptera frugiperda (Sf9) cells
nfected with AcNPVgag-pro were examined. The cyto-
lasm of these cells (Fig. 6) contained large vacuoles
hat were not observed in cells infected with either wild-
ype baculovirus or AcNPVgag. Unlike the case for Ac-
PVgag-infected insect cells, the examination at higher
agnification of cells infected with AcNPVgag-pro
howed no electron-dense evaginations at the plasma
embrane (data not shown). Moreover, no budding par-
FIG. 4. Thin-section electron microscopy of material pelleted from
the culture medium of Sf9 insect cells infected with AcNPVgag. The
culture media were harvested 48 h postinfection and cleared to elim-
inate aggregates, and the two-step sucrose gradient method (see
Materials and Methods) was performed. In pellet 40% (A) and pellet
25% (B), only baculoviruses particles are present in both. Magnification,
378,000; bar, 128 nm.icles were found at the cell membranes. These results
emonstrate that expression of Gag-Pro polyprotein innsect cells resulted in a premature and extensive mat-
ration of the Gag protein.
xpression of Gag and Gag-Pro in human 293 cells
To test whether the inability of Pr53Gag polyprotein to
e released as VLPs from insect cells reflects an intrin-
ic property of this protein or rather results from a failure
f the Pr53Gag protein to properly assemble and bud from
nsect cells, we transiently expressed Gag and Gag-Pro
recursor proteins in human 293 cells using a vector
ontaining an SV40 promoter. Recombinant expression
ectors pKgag and pKgag-pro, carrying gag and gag-pro
enes, respectively, were constructed. The fragments
ere cloned into the pKCR3T7P11 expression vector
uch that the rabbit b-globin sequences 59 of the HTLV-I
NA provides an intron with its flanking splice signals.
his vector does not contain the RRex element and thus
llows efficient expression of HTLV-I proteins indepen-
ent of Rex protein. However, we observed that the
ddition of the HTLV-I Tax and Rex regulatory proteins in
rans allowed a two- to threefold increase in the protein
xpression level.
We transfected human 293 cells with either pKgag or
Kgag-pro plasmids DNAs, and the proteins were radio-
abeled 48 h after transfection. Synthesis of Gag and
ag-Pro polyproteins was detected by immunoprecipita-
ion using a monoclonal antibody to p24. Pr53Gag was
rominently detected in both cell lysates from pKgag-
nd pKgag-pro-transfected cells (Fig. 7A, lanes 1 and 2,
espectively). Capsid protein p24CA was found only in
ysate from pKgag-pro-transfected cells as expected (Fig.
A, lane 2). No Gag protein was immunoprecipitated
rom mock transfected cell extract (Fig. 7A, lane 3). Thus
FIG. 5. Expression of gag-pro genes in insect cells results in efficient
processing of Pr53Gag precursor polyprotein. Sf9 cells were infected
with AcNPVgag-pro and harvested 48 h postinfection. Cell lysates were
analyzed by SDS–PAGE and immunoblotting using serum from an
HTLV-I-positive patient (lane 3) and monoclonal antibodies directed
against p19MA (lane 1) or p24CA (lane 2). Gag, p37, p19MA, and p24CA
proteins are indicated as well as the positions of the molecular mass
markers (in kDa).
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602 BOUAMR ET AL.when expressed as a Gag-Pro fusion protein, the Gag
polyprotein is specifically cleaved into p24CA protein,
suggesting the translation of an active protease as a
component of the Gag-Pro polyprotein.
To analyze Pr53Gag release from human 293 cells, cul-
ure media of 293 cells transfected with either pKgag or
Kgag-pro constructs were collected 48 h after transfec-
ion and centrifuged on a 20% sucrose cushion. Immu-
oprecipitation analysis using a monoclonal antibody to
24 showed that pelletable forms of Pr53Gag and p24CA
proteins were released into the culture media of pKgag-
and pKgag-pro-transfected cells (Fig. 7B, lanes 1 and 2,
respectively). No Gag or CA protein was found in the
culture medium of mock transfected cells (Fig. 7C, lane
3). No soluble Gag or CA was immunoprecipitated from
the culture media of 293 cells transfected with either
pKgag (Fig. 7C, lane 1) or pKgag-pro (Fig. 7C, lane 2).
Altogether, these results showed that Pr53Gag and p24
apsid produced in 293 cells were effectively released
nto the culture medium. These proteins were sedi-
ented through a 20% sucrose cushion, indicating that
FIG. 6. Thin-section electron microscopy of Sf9 cells infected wit
cytoplasmic vacuoles. Magnification, 39450; bar, 1.05 mm.hey are present in the culture medium as particulate
orm. Therefore, Pr53Gag protein has the ability to beFIG. 7. Expression and release of Gag and Gag-Pro polyproteins
from human 293 cells. Whole-cell extracts from either mock-transfected
293 cells (lane 3) or cells transfected with either pKgag (lane 1) or
pKgag-pro (lane 2) were harvested 48 h postinfection. Intracellular Gag
protein (A) and Gag proteins released into the culture medium, cen-
trifugated on 20% sucrose cushion, and found in the pellets (B) or
supernatants (C) were immunoprecipitated with a monoclonal antibody
anti-p24 and visualized by autoradiography. Positions of HTLV-1 Gag
and CA proteins and molecular mass markers (in kDa) are indicated.
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603HTLV-I PARTICLE RELEASE FROM INSECT AND MAMMALIAN CELLSsecreted from human 293 cells, probably by budding and
release as VLPs.
N-terminal myristylation residue, glycine 2 (G2), is
required for Gag polyprotein release
To examine the role of the N-terminal glycine (G2) in
the release of HTLV-I Pr53Gag polyprotein, the glycine G2
residue, which has been shown to be myristylated in
yeast (Hayakawa et al., 1977), was substituted with an
alanine residue. When cell lysates from 293 cells trans-
fected with either the mutant pKMyr0 or wild-type pKgag
construct were analyzed by immunoprecipitation using a
monoclonal antibody to p24, similar protein expression
patterns were observed, and Pr53Gag was detected in
both lysates (Fig. 8A, lanes 1 and 2). No Gag polyproteins
were immunoprecipitated from the culture media of 293
cells transfected with pKMyr0 plasmid, showing that no
Pr53Gag was released (Fig. 8B, lane 1). In contrast, 293
ells transfected with pKgag plasmid expressing wild-
ype Gag polyprotein released pelletable Pr53Gag in the
culture media (Fig. 8B, lane 2). No Gag polyprotein was
found in the cell lysate or the culture media of mock
transfected cells (Figs. 8A, lane 3, and 8B, lane 3, re-
spectively). These data demonstrate that in HTLV-I Gag
polyprotein, an intact myristylation residue G2 is required
for Pr53Gag release from human 293 cells, implying that
the targeting of Gag polyprotein to the plasma mem-
brane is crucial for its release. This result also shows
that the release of the HTLV-I Gag polyprotein is a spe-
cific event supporting our hypothesis that HTLV-I Pr53Gag
FIG. 8. An intact N-terminal glycine residue is required for HTLV-I
ag polyprotein release. Mock-transfected 293 cells (lane 3) and 293
ells transfected with either pKMyr0 (lane 1) or pKgag construct (lane
) were harvested 48 h postinfection. Intracellular Gag proteins (A) or
ag proteins released into the culture medium and pelleted through a
0% sucrose cushion (B) were immunoprecipitated with a monoclonal
ntibody anti-p24 and visualized by autoradiography. Position of Pr53Gag
protein and molecular mass markers (in kDa) are indicated.follows a type-C morphogenesis pathway to form and
release particles from 293 human cells.HTLV-I Gag polyproteins released from human 293
cells are enveloped by a lipid membrane
Expression of HTLV-I gag or gag-pro genes in human
93 cells led to the release of immature Gag polyproteins
r processed Gag products into the culture medium,
espectively. The released proteins were sedimented
hrough a 20% sucrose cushion, indicating that they were
eleased as particulate forms. In an attempt to determine
hether the Pr53Gag proteins were secreted as VLPs or
rather as nonenveloped aggregates, the accessibility of
the pelleted Gag polyproteins to trypsin digestion was
tested under different conditions. As an internal control
to the experiment, we chose to subject BLV virions,
released from a high-producing BLV virion cell line, FLK-
BLV cell (Mamoun et al., 1981), to trypsin digestion in
parallel with the released HTLV-I Gag and under identi-
cal conditions. The results of trypsin digestion assay are
shown in Fig. 9. In the absence of trypsin, a band of 53
kDa, the Gag precursor was detected (lane 5), whereas
this band was absent in mock transfected cells (lane 1).
In lane 9, a rabbit polyclonal antibody directed against
BLV CA protein detected a band of approximately 53 kDa
corresponding to the unprocessed BLV Gag precursor.
When protein samples were subjected to trypsin diges-
tion in the presence of protease inhibitors and Triton
X-100 detergent, HTLV-I Pr53Gag (lane 8) and BLV Gag
(lane 12) remained detected. When Triton X-100 deter-
gent and protease inhibitors were omitted, a comparable
amount of HTLV-I Pr53Gag (lane 6) and BLV Gag (lane 10)
as recognized, indicating that both precursor proteins
ere similarly protected from trypsin digestion. By con-
rast, when only the protease inhibitors were omitted and
riton X-100 detergent was added, no proteins were
etected (lanes 7 and 11), showing that HTLV-I Pr53Gag
FIG. 9. Trypsin digestion resistance of Gag polyproteins released
from human 293 cells. Human 293 cells were mock-transfected (lanes
1–4) or cells transfected with the pKgag plasmid (lanes 5–8) and
FLK-BLV cells producing BLV virions were harvested 48 h posttrans-
fection. HTLV-I Gag VLPs and BLV viral particles released into the
culture medium were pelleted through 20% sucrose cushion. The pel-
leted proteins (lanes 1–8) and BLV virions (lanes 9–12) were mock
treated (lanes 1, 5, and 9), treated with trypsin alone (lanes 2, 6, and 10),
treated with trypsin and Triton X-100 detergent (lanes 3, 7, and 11), or
treated with trypsin, Triton X-100 detergent, and protease inhibitors
(lanes 4, 8, and 12) and analyzed by SDS–PAGE and immunoblotting
using either monoclonal antibodies directed against both HTLV-I
p19MA and p24CA or a rabbit serum directed against BLV CA protein.
The positions of Gag precursors are indicated.
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604 BOUAMR ET AL.and BLV Gag precursors were fully digested by trypsin.
These results show that the HTLV-I Gag polyproteins
released from 293 cells, like the BLV Gag proteins
present in BLV virions, are protected by a lipid mem-
brane. This revealed that HTLV-I Gag polyproteins are
released from 293 cells by budding at the plasma mem-
brane as enveloped VLPs.
DISCUSSION
The HTLV-I Gag protein expressed in insect cells
does not assemble as VLPs
In the present study, we demonstrated that Pr53Gag
polyprotein, when expressed alone or as Gag-Pro
polyprotein in recombinant baculovirus-infected insect
cells, is unable to assemble particles budding from the
plasma membrane. This result was unexpected because
previous reports have clearly established that the syn-
thesis of different retroviral Gag proteins yielded the
formation and release of VLPs from insect cells (Del-
chambre et al., 1989; Gheysen et al., 1989; Kaker et al.,
1999; Royer et al., 1991; Sommerfelt et al., 1993; Taka-
hashi et al., 1999). Our results clearly showed that HTLV-I
Pr53Gag precursor protein is efficiently and highly pro-
uced in insect cells using a recombinant baculovirus
arrying the entire gag gene. Smaller proteins were also
etected and probably result from proteolytic degrada-
ions by host cell proteases. A similar phenomenon was
reviously described for Gag polyproteins of other retro-
iruses when expressed in insect cells (Gheysen et al.,
989; Jacobs et al., 1989) but did not affect VLP formation.
hus the stability of Pr53Gag protein is comparable to the
tability of other retroviral Gag proteins expressed in
nsect cells. The Pr53Gag polyprotein was targeted to the
plasma membrane, where it massively accumulates and
forms evaginations of various sizes and shapes. Protrud-
ing extensions were also observed at the plasma mem-
brane, and amorphous structures were found in the pe-
riphery of the cells. However, Pr53Gag did not bud and
elease from insect cells as VLPs. The curves observed
t the plasma membrane were rather reminiscent of
elayed and/or arrested particle morphogenesis fea-
ures.
In insect cells, the inability of Pr53Gag to assemble and
release immature particles into the culture medium may
be caused by (1) the inability of HTLV-I Gag, by itself, to
drive the particle formation in the absence of other viral
components, (2) the lack of a host factor that is required
at a late stage in the particle budding process, or (3)
structural problems due to an interaction between a
cellular protein and Gag polyproteins that hide a func-
tional domain of Gag and thus sterically hamper the
assembly of Gag monomers and/or the release by bud-
ding.
n
HHTLV-I protease does not restore the defect of Gag
polyprotein to assemble and bud from cell membrane
It has been previously reported that HIV-1 viral pro-
tease could influence the particle morphogenesis and
release (Kaplan et al., 1994). Even though the HIV-1 Pol
region is not known to be required for particle formation
and the overexpression of HIV-1 Gag-Pol was shown to
suppress the particle formation (Karacostas et al., 1993;
rausslich, 1991), it was described that in the presence
f HIV-1 protease inhibitor, particle formation is arrested
n an early step of particle development (Hughes et al.,
993; Schatzl et al., 1991). Moreover, it has been shown
hat feline leukemia virus Gag-Pro and Mason-Pfizer
onkey virus (M-PMV) Gag-Pro-Pol precursor polypro-
eins have the ability to form and release VLPs from
nsect cells (Sommerfelt et al., 1993; Thomsen et al.,
992). We elected to express HTLV-I Gag-Pro precursor
rotein in insect cells and demonstrated that Pr53Gag
protein was cleaved into the appropriately sized prod-
ucts, p24 Capsid and p19 Matrix, revealing the expres-
sion of an active protease. TEM analysis showed that
insect cells expressing Gag-Pro precursor polyproteins
contain numerous large vacuoles in the cytoplasm,
which are probably due to the overexpression and the
accumulation of high amounts of active viral protease in
the cytoplasm. Moreover, no budding particle or mem-
brane evaginations were found at the cell membrane.
These results are in agreement with previous studies
carried out with HIV-1 in which it was shown that over-
expression of HIV-1 Gag-Pol polyprotein abolished par-
ticle formation (Karacostas et al., 1993; Krausslich, 1991).
Therefore, the expression of Pro as Gag-Pro polyprotein
did not complement the Gag defect in HTLV-I particle
morphogenesis and release from insect cells.
HTLV-I Gag protein, expressed in human 293 cells, is
released into the culture medium
Our results showed that Pr53Gag, when expressed in
human 293 cells in the absence of any other viral pro-
teins, is released into the culture medium. Similarly, ex-
pression of HTLV-I Gag-Pro in human 293 cells results in
the release of p24CA protein into the culture medium.
Both Pr53Gag and p24 Capsid released in the culture
edium could be pelleted through a 20% sucrose cush-
on. Moreover, no soluble form of Pr53Gag or p24 Capsid
protein was found in the culture supernatants, suggest-
ing that all of the Pr53Gag and p24 Capsid detected in the
culture media are particle-associated proteins. Our data
also demonstrated that when the myristylation residue,
the N-terminal G2 residue in Pr53Gag, is mutated, no Gag
protein is found in the culture media, indicating that the
N-terminal G2 in Pr53Gag is essential for its release. This
uggests that like for other retroviruses (Bryant and Rat-
er, 1990; Jacobs et al., 1989; Rein et al., 1987; Rhee and
unter, 1987), the N-terminal G2 in Pr53Gag is myristylated
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plasma membrane to specifically achieve assembly and
release of particles. Our result from the trypsin digestion
analysis clearly demonstrated that Pr53Gag particulate
orms released from the 293 cells are protected with a
ipid bilayer. This shows that Pr53Gag particulate forms
released from the 293 cells are enveloped during bud-
ding from the plasma membrane. Taken together, our
results indicate that the Pr53Gag particulate forms re-
leased from the 293 cells are the consequence of an
assembly process that took place at the plasma mem-
brane, yielding budding and release of enveloped VLPs.
Is a cellular factor, essential for HTLV-I Gag release,
absent in insect cells?
Our data showed that the inability of Gag polyprotein
to release VLPs from insect cells is not an inherent
property of HTLV-I Pr53Gag but rather seems to be due to
he lack of a host factor in insect cells, because HTLV-I
r53Gag is released from the human 293 cells. Cell line-
dependent assembly and/or release of HIV-1, HIV-2, and
M-PMV particles has been previously described (Dru et
al., 1994; Parker and Hunter, 2000; Shioda and Shibuta,
1990; Voss et al., 1992). These studies proposed the
hypothesis that different cellular factors may be involved
during the retroviral particle morphogenesis. Wills et al.
(1994) first reported that the Rous sarcoma virus (RSV)
p2b protein, which contains the PPPPY motif, is needed
late in the budding process of RSV virus. This region has
been defined as the late (L) assembly domain of RSV
Gag polyprotein (Parent et al., 1995), and its critical res-
idues have been characterized (Xiang et al., 1996). More
recently, the RSV PPPPY motif has been shown to bind to
the WW domain of signaling cellular protein YAP (Yes-
associated-protein) in vitro (Garnier et al., 1996). Yasuda
and Hunter (1998) recently demonstrated that a PPPY
motif in the M-PMV Gag protein plays a key role in late
stage of virus budding. These observations support the
hypothesis that host proteins are involved in the final
stages of retroviral budding and particle release. Se-
quence comparison of HTLV-I Gag with other retroviral
Gag proteins indicates that HTLV-I Gag contains adja-
cent PPPY and PTAP motifs located at the C terminus of
MA protein. Both motifs are presumed to operate late in
budding, mediating the pinching-off step (Gottlinger et
al., 1991; Wills et al., 1994). PPPY residues are highly
conserved in the HTLV/BLV group (Katoh et al., 1991;
Shimotohno et al., 1985) and among many retroviruses
(Pepinsky et al., 1986). Regarding the PTAP motif, this
sequence is also highly conserved in all lentiviruses
except Equine Infectious Anemia Virus (EIAV) and is
generally located between MA and CA domains of the
Gag polyprotein. Indeed, two PTAP motifs are found in p6
protein of some isolates of HIV-2 and in both Simian
immunodeficiency virus p6 and MA proteins. HTLV-I isunique in that the MA protein contains both highly con-
served motifs (PPPPY and PTAP) that have been shown
to provide the late assembly function in other retrovi-
ruses. It will be interesting to determine whether HTLV-I
utilizes one or both of these motifs as a late domain.
It is likely that retroviruses recruit cellular proteins
and/or factors during their life cycle to favor their own
replication and spread. The morphogenesis of HTLV-I
particle appears to be a sensitive process and has spe-
cific requirements, because it typically yields poorly in-
fectious particles with an ill-defined capsids (Gelder-
blom, 1991). Although further experiments are needed to
elucidate HTLV-I particle assembly and release, the
present study provides a first glimpse of the prerequire-
ment of cellular factor or factors implicated in HTLV-I
particle budding.
MATERIALS AND METHODS
Cells and virus
Sf9 cells were grown as monolayers at 28°C in Grace
medium (Sigma Chemical Co., St. Louis, MO) supple-
mented with 10% FBS. Human 293 cells were maintained
at 37°C with 5% CO2 in Dulbecco’s modified Eagle’s
medium (DMEM; GIBCO, Grand Island, NY) supple-
mented with 10% FBS. Wild-type AcNPV DNA was pre-
pared and stored using the method described by Sum-
mers and Smith (1987).
Construction of transfer vector baculoviruses
We inserted the complete Gag-Pro protein coding se-
quence from the pMT-2 plasmid (Clarke et al., 1983) as
an AvrII–ApaI fragment (bp 441–2429) into the XbaI–SmaI
sites of pBSM13-derived vector. The resulting plasmid,
pBSgag-pro, contains the entire coding region of the
HTLV-I Gag precursor, the entire viral protease, and a
short fragment of the 59 end of the pol gene. To construct
a plasmid carrying only the entire Gag coding sequence,
the 39 end of the gag gene was reconstituted by PCR.
The upstream primer A, 59-TGCAGCAGTTTGAC-
CCCACTG-39 (Genset, Paris, France), corresponds to the
sequence of Gag between codons 1347 and 1369.
The downstream primer B, 59-CCGAATTCGAGCTCGGT-
ACCTTAAACCTCCCCCCCTATGGAG-39 (Genset), inserts
coRI, SacI, and KpnI sites downstream of the TAA stop
odon of the HTLV-I gag gene. The resulting PCR frag-
ent was digested with BstXI (codon 1604) and EcoRI
(upstream of the TAA codon) enzymes. The digested PCR
product was cloned into the equivalent sites of pBSgag-
pro to obtain pBSgag. Plasmids pBSgag and pBSgag-pro
were digested with HindIII, treated with nuclease S1, and
then digested with KpnI. The resulting fragments were
ligated into pGmAc115T (Royer et al., 1991), which had
been digested with BglII, treated by Klenow’s enzyme,
and digested with KpnI. The recombinant baculovirus
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gag-pro genes under the control of the polyhedrin pro-
moter.
Mammalian expression vectors
The expression vector pKCR3T7P11 is derived from
pKCR3 plasmid (O’Hare et al., 1981), which had been
modified by insertion of a polylinker sequence (HindIII,
PstI, SalI, XbaI, BamHI, SmaI, EcoRI) in the unique EcoRI
ite situated at nucleotide 1640. pKCR3T7P11 contains
n SV40 early promoter, an unique BamHI site, an intron
lanked by exons 2 and 3 of the rabbit b-globin gene, and
the SV40 polyadenylation site (downstream of the
polylinker sequence). To construct pKgag and pKgag-
pro, pBSgag and pBSgag-pro were digested with HindIII
and EcoRI, respectively, and the resulting fragments
were ligated into the HindIII–EcoRI sites of pKCR3T7P11.
To make the pKMyr0 plasmid, which carries the entire
gag gene with glycine 2 substituted with an alanine,
site-directed mutagenesis was performed on the pBSgag
plasmid using primer C (Genset) 59-CTGCAGGTC-
CACTCTAGGCAATGGCCCAAATCTTT-39 and according
to the manufacturer’s instructions (Clontech, Palo Alto,
CA). The sequence of the resulting plasmid was verified
by DNA sequencing, and gagMyr0 gene was then in-
serted into the pKCR3T7P11 vector as described above.
To provide Tax and Rex proteins in trans, we used
IItatORF plasmid (Dokhe´lar et al., 1989; a kind gift from
r. M.-C. Dokhe´lar, Institut G. Roussy, Villejuif, France).
otransfection and purification of recombinant
aculoviruses
One microgram of wild-type AcNPV DNA was mixed
ith 5 mg of recombinant baculovirus transfer vector
NA in serum-free medium, as well as 40 ml of DOTAP
eagent (Boehringer, Mannheim, Indianapolis, IN). After
h, the mixture was added to Sf9 cells seeded at a
ensity of 1.5 3 106 cells/5 ml (T25 flask). At 3–4 days
after cotransfection, the medium was harvested, and
occlusion body-negative plaques were selected visually.
Recombinant viruses were plaque-purified twice, and
titered stocks were made after Western blot analyses to
confirm the presence of HTLV-I-specific proteins.
Immunodetection of proteins from recombinant
baculovirus-infected cells
At 48 h postinfection, Sf9 cells were washed with PBS,
harvested in sample buffer (60 mM Tris–HCl pH 6.8, 1%
SDS, 1% b-mercaptoethanol, 10% glycerol, 0.1% bromo-
phenol blue), and then heated for 5 min at 100°C before
loading on SDS–PAGE (Laemmli, 1970). Western blot
analysis was performed either with a monoclonal anti-
body against Matrix (kindly provided by C. Desgranges,
Lyon, France) or with a monoclonal antibody againstCapsid (Advanced Bioscience Laboratories; kindly pro-
vided by A. Elkharroubi, Bethesda, MD). After incubation
with a anti-mouse IgG horseradish peroxidase conjugate
(Jackson Laboratories) and a chemiluminescent sub-
strate (ECL; Amersham, Arlington Heights, IL), the mem-
brane was exposed to a radiographic film (Hyperfilm-
ECL; Amersham).
Transfection of mammalian cells, metabolic labeling,
and immunoprecipitation
The day before transfection, human 293 cells (Graham
et al., 1977; Harrison et al., 1977) were prepared to reach
70% confluence in a 100-mm plate, and transfections
were performed with 10 mg according to the calcium-
hosphate method. At 42 h posttransfection, the cells
ere labeled for 5 h in DMEM supplemented with 100
mCi/ml [35S]cysteine-methionine. Cells were lysed with 1
ml of RIPA buffer (0.5% Nonidet P-40, 0.5% deoxycholate,
1 mM PMSF, 1 mM Na2HPO4, 0.15 M NaCl, 10 mM
Tris–HCl, pH 7.8), and Gag and Capsid proteins were
immunoprecipitated with the monoclonal antibody
against Capsid. Antigen–antibody complexes attached to
protein A–Sepharose beads were solubilized by heating
in sample buffer and separated on SDS–PAGE. Gels
were fixed and incubated in Amplify fluorographic re-
agent (Amersham Life Science) and then dried. Radioac-
tive bands were visualized using medical imaging film
(3M).
Analysis of Gag secretion
HTLV-I Pr53Gag was sought in the culture media of Sf9
cells infected with gag recombinant baculoviruses using
the two-step sucrose gradient method (Sommerfelt et al.,
1993). This method aims to partially separate the bacu-
lovirus particles from the retroviral VLPs by sedimenta-
tion on two superimposed 40% w/w and 25% w/w su-
crose cushions. When the culture medium of Sf9 infected
cells is span on the two cushions, the baculovirus par-
ticles are first pelleted through the 40% sucrose cushion,
whereas the retroviral VLPs are arrested at the interface
with the 25% cushion. The VLPs are carefully collected
and sedimented through a 25% cushion, and the soluble
Gag proteins remain in the upper phase and are subse-
quently immunoprecipitated as described earlier. Culture
media from 293 cells expressing Gag proteins were
harvested 48 h posttransfection and cleared by centrifu-
gation at 14,000 rpm for 10 min at 4°C, loaded onto a 20%
w/w sucrose cushion, and centrifuged at 4°C for 2 h at
20,000 rpm using an SV40 Beckman rotor. The pellets
were resuspended in RIPA buffer, and the Gag proteins
were immunoprecipitated using an antibody against the
capsid and analyzed by autoradiography as described
earlier.
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607HTLV-I PARTICLE RELEASE FROM INSECT AND MAMMALIAN CELLSPreparation for electron microscopy
For thin sectioning, Sf9 cells were harvested 48 h
postinfection and gently scraped from the plastic surface
into PBS. Cell pellets (or samples pelleted through a
sucrose cushion) were fixed with 2.5% glutaraldehyde in
0.1 M phosphate buffer (pH 7.4) and postfixed with 1%
OsO4. After dehydration in a graded series of cold etha-
ol, the samples were embedded in Epon 812 resin.
ltrathin sections (90 nm) were then doubly stained with
ranyl acetate and lead citrate. The stained sections
ere observed with a Philips CM10 electron microscope.
rypsin digestion assay
At 48 h after transfection or incubation, the culture
edium from cells expressing HTLV-I Gag or FLK-BLV
ells (Mamoun et al., 1981) constitutively producing BLV
iral particles was harvested and precleared as de-
cribed earlier, loaded onto a 20% w/w sucrose cushion,
nd centrifugated at 36,000 3 g for 2 h at 4°C. The
elleted material was resuspended into TNE 13 buffer
10 mM Tris, 100 mM NaCl, 1 mM EDTA, pH 7.9) and
ivided into four equal aliquots. The trypsin digestion
ssay was performed in a 50-ml reaction volume in TNE
13, under four different conditions: (1) the first aliquot
was mock treated, (2) the second aliquot was treated
with trypsin alone (0.2 mg/ml), (3) the third aliquot was
treated with trypsin and Triton X-100 (1%) detergent, and
(4) the fourth aliquot was treated with trypsin, Triton
X-100 detergent, and protease inhibitors cocktail (30 mM
aprotinin, 435 mM leupeptine, 500 mM PMSF). Samples
were incubated 30 min at 37°C. The reaction was
stopped by the addition of the protease inhibitor cocktail
in each sample and incubated for 5 min on ice. Then, 20
ml of a 43 dissociation buffer was added, and the sam-
les were boiled for 5 min. Proteins were separated by
DS–PAGE and analyzed by immunoblot using monoclo-
al antibodies directed against both HTLV-I p19MA and
24CA or using a rabbit serum raised against BLV CA.
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